Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

None of the eteplirsen-treated patients reached an LVEF below 50%, compared with 22.1% of patients in the control group. | Image credit: inthasone - stock.adobe.com

Eteplirsen Treatment Linked to Slower Cardiac Decline in DMD

By Rose McNulty

April 11th 2025

None of the eteplirsen-treated patients reached a left ventricular ejection fraction below 50% compared with 22.1% of patients in the control group.

Seniors receiving health care | Image credit: Adobe.com

Sutter Health, SCAN Announce Partnership to Launch New MA Products, Joint Venture Health Plan

By Mary Caffrey

April 11th 2025

The California-based entities plan to offer new Medicare Advantage (MA) products in select counties by this fall.

Patient self reporting or intentional physical examinations by clinicians remain the main avenues by which suspected skin cancers are identified. | Image credit: anna.stasiia - stock.adobe.com

Novel Methods Could Reshape Skin Cancer Diagnostics

By Jared Kaltwasser

April 10th 2025

Investigators highlighted Raman spectroscopy, a noninvasive diagnostic technology that could lead to faster, earlier detection of skin cancer.

Based on the model, over 3 million MACE were projected over the following 10 years, approximately 496,000 of which could be prevented with the use of semaglutide. | Image credit: peter hansen - stock.adobe.com

Semaglutide Use Could Prevent Up to 2 Million MACE in 10 Years, Model Suggests

By AJMC Contributor

April 9th 2025

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

...

37 38 39 40 41

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions